Edition:
United Kingdom

Medicines Co (MDCO.OQ)

MDCO.OQ on NASDAQ Stock Exchange Global Select Market

26.59USD
22 Oct 2018
Change (% chg)

$-0.31 (-1.15%)
Prev Close
$26.90
Open
$27.00
Day's High
$27.00
Day's Low
$25.96
Volume
261,856
Avg. Vol
284,497
52-wk High
$41.57
52-wk Low
$24.45

Latest Key Developments (Source: Significant Developments)

The Medicines Company Announces Recommendation By Independent Data Monitoring Committee To Continue Inclisiran
Monday, 1 Oct 2018 

Oct 1 (Reuters) - Medicines Co ::THE MEDICINES COMPANY ANNOUNCES RECOMMENDATION BY INDEPENDENT DATA MONITORING COMMITTEE TO CONTINUE INCLISIRAN PHASE III TRIALS FOLLOWING FOURTH REVIEW OF UNBLINDED DATA.MEDICINES CO - PHASE III TRIALS OF INCLISIRAN PROGRESSING AS PLANNED WITH NO MATERIAL SAFETY OBSERVATIONS TO DATE.MEDICINES CO - IDMC FOR ONGOING INCLISIRAN PHASE III TRIALS HAS RECOMMENDED THAT TRIALS CONTINUE AS DESIGNED AND CONDUCTED, WITHOUT MODIFICATION.MEDICINES CO - DATA READOUT FOR INCLISIRAN PHASE III PROGRAM EXPECTED IN SECOND HALF OF 2019.  Full Article

The Medicines Company Reports Q2 GAAP Loss Per Share $0.74
Wednesday, 1 Aug 2018 

Aug 1 (Reuters) - Medicines Co ::THE MEDICINES COMPANY REPORTS SECOND-QUARTER 2018 RESULTS.Q2 GAAP LOSS PER SHARE $0.74 FROM CONTINUING OPERATIONS.Q2 ADJUSTED NON-GAAP LOSS PER SHARE $0.63 FROM CONTINUING OPERATIONS.Q2 EARNINGS PER SHARE VIEW $-0.60 -- THOMSON REUTERS I/B/E/S.AT JUNE 30, CO HAD $162.5 MILLION IN CASH AND CASH EQUIVALENTS, COMPARED TO $151.4 MILLION AT END OF 2017.  Full Article

Medicines Co Announces Recommendation By Independent Committee To Continue Inclisiran Phase III Trials
Wednesday, 27 Jun 2018 

June 27 (Reuters) - Medicines Co ::THE MEDICINES COMPANY ANNOUNCES RECOMMENDATION BY INDEPENDENT DATA MONITORING COMMITTEE TO CONTINUE INCLISIRAN PHASE III TRIALS FOLLOWING THIRD REVIEW OF UNBLINDED DATA.MEDICINES CO - PHASE III TRIALS OF INCLISIRAN PROGRESSING AS PLANNED WITH NO MATERIAL SAFETY OBSERVATIONS TO DATE.MEDICINES CO - "CONTINUE TO ADVANCE INCLISIRAN PHASE III PROGRAM ON HIGHLY-EFFICIENT BASIS, WITH DATA READOUT EXPECTED IN SECOND HALF OF 2019".  Full Article

The Medicines Company Announces Chief Financial Officer Transition
Wednesday, 28 Mar 2018 

March 28 (Reuters) - Medicines Co ::THE MEDICINES COMPANY ANNOUNCES CHIEF FINANCIAL OFFICER TRANSITION.APPOINTS CHRISTOPHER VISIOLI AS CHIEF FINANCIAL OFFICER AND TREASURER OF COMPANY​.‍ VISIOLI SUCCEEDS WILLIAM O'CONNOR, WHO IS RETIRING FROM COMPANY AFTER SERVING AS CHIEF ACCOUNTING OFFICER AND THEN CFO.  Full Article

State Street Global Advisors Announces Impact Of Receiving Settlement Payment
Friday, 5 Jan 2018 

Jan 5 (Reuters) - State Street Corp ::STATE STREET GLOBAL ADVISORS ANNOUNCES IMPACT OF RECEIVING SETTLEMENT PAYMENT.SPDR EXCHANGE TRADED FUND - RECEIVED PAYMENT AS AUTHORIZED CLAIMANT FROM A CLASS ACTION SETTLEMENT RELATED TO MEDICINES COMPANY​.  Full Article

Melinta Therapeutics Enters Agreement To Acquire Infectious Disease Business From The Medicines Company
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - Melinta Therapeutics, Inc. ::MELINTA THERAPEUTICS ENTERS INTO AGREEMENT TO ACQUIRE INFECTIOUS DISEASE BUSINESS FROM THE MEDICINES COMPANY.  Full Article

Medicines Company Announces Definitive Agreement To Sell Its Infectious Disease Business Unit To Melinta Therapeutics
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - Medicines Co ::THE MEDICINES COMPANY ANNOUNCES DEFINITIVE AGREEMENT TO SELL ITS INFECTIOUS DISEASE BUSINESS UNIT TO MELINTA THERAPEUTICS.MEDICINES - TO SELL INFECTIOUS DISEASE BUSINESS UNIT TO MELINTA THERAPEUTICS FOR $270 MILLION IN UPFRONT CONSIDERATION AND GUARANTEED PAYMENTS.MEDICINES - DEAL INCLUDES TIERED ROYALTY PAYMENTS OF 5% TO 25% ON WORLDWIDE NET SALES OF VABOMERE, ORBACTIV AND MINOCIN IV, AMONG OTHER THINGS.MEDICINES CO - MELINTA TO PAY DEAL CONSIDERATION, INCLUDING $165 MILLION IN CASH, PAID AT CLOSING, MELINTA SHARES WITH A MARKET OF $55 MILLION, AMONG OTHERS.MEDICINES CO - ‍CONCURRENT WITH EXECUTION OF DEAL, CO RECEIVED BINDING COMMITMENT FROM DEERFIELD MANAGEMENT AFFILIATE.MEDICINES CO - DEERFIELD MANAGEMENT ‍AFFILIATE COMMITTED TO PROVIDE FINANCING TO MELINTA IN CONNECTION WITH DEAL,TO PROVIDE A $100 MILLION CREDIT FACILITY​.  Full Article

Medicines Co names Fred Eshelman executive chairman
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - Medicines Co -:The Medicines Company names Dr. Fred Eshelman as executive chairman; appoints Geno Germano to its board of directors.Medicines Co - ‍appointed FREDRIC N. ESHELMAN, company's current chairman of board, to newly created position of executive chairman​.Medicines Co - ‍appointments are effective immediately​.  Full Article

SymBio Pharmaceuticals says arbitration against The Medicines Company
Monday, 13 Nov 2017 

Nov 13 (Reuters) - SymBio Pharmaceuticals Ltd <4582.T>:Says co initiated an arbitration against The Medicines Company (MDCO) on Oct. 11, under the rules of International Chamber of Commerce, seeking damages arising out of MDCO's repudiation of the license agreement entered into between the co and MDCO on October 5, 2015, for the exclusive rights to develop and commercialize the patient-controlled pain management drug "SyB P-1501" (or "IONSYS") in Japan.Says the co seeks damages of $82 million (about 9 billion yen).  Full Article

The Medicines Co and Alnylam Pharmaceuticals to start phase III clinical trials of inclisiran
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Medicines Co :The Medicines Company and Alnylam Pharmaceuticals announce initiation of phase III clinical trials of inclisiran.Medicines Co - ‍continues to expect that all of these trials will commence before end of 2017​.  Full Article

REFILE-UPDATE 2-FDA knocks back Achaogen's drug for bloodstream infection

June 26 The U.S. Food and Drug Administration cleared Achaogen Inc's antibiotic to treat adults with complicated urinary tract infections, but shares slumped 25 percent as the drug failed to win approval for treating bloodstream infections.